SYRE (Spyre Therapeutics) Median PS Value : $0.00 (As of Apr. 01, 2025)

View and export this data going back to 2016. Start your Free Trial

What is Spyre Therapeutics Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Spyre Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0. Spyre Therapeutics's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.

As of today (2025-04-01), Spyre Therapeutics's share price is $16.135. Spyre Therapeutics's Median PS Value is $0.00. Therefore, Spyre Therapeutics's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Spyre Therapeutics's Median PS Value or its related term are showing as below:

SYRE's Price-to-Median-PS-Value is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.67
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Spyre Therapeutics Median PS Value Historical Data

The historical data trend for Spyre Therapeutics's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spyre Therapeutics Median PS Value Chart

Spyre Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Median PS Value

Get a 7-Day Free Trial

Spyre Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Median PS Value	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Spyre Therapeutics's Median PS Value

For the Biotechnology subindustry, Spyre Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spyre Therapeutics's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Spyre Therapeutics's Price-to-Median-PS-Value falls into.

Save Embed

;

Save Embed

;

Spyre Therapeutics Median PS Value Calculation

Spyre Therapeutics's Median PS Value for today is calculated as

Median PS Value	=	Revenue per Share (TTM)	*	10-Year Median PS Ratio
	=	0	*
	=	0.00

10-Year Median PS Ratio is .
Spyre Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.

Spyre Therapeutics (NAS:SYRE) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Spyre Therapeutics's Price to Median PS Value for today is calculated as

Price to Median PS Value	=	Share Price	/	Median PS Value
	=	16.135	/	0.00
	=

Spyre Therapeutics Median PS Value Related Terms

Thank you for viewing the detailed overview of Spyre Therapeutics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Spyre Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spyre Therapeutics Inc (NAS:SYRE) » Definitions » Median PS Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453

Website

https://www.spyre.com

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Executives

Scott L Burrows	officer: Chief Financial Officer	C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Heidy King-jones	officer: See Remarks	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Fairmount Healthcare Co-invest L.p.	director, 10 percent owner	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Peter Evan Harwin	director, 10 percent owner	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Funds Management Llc	director, 10 percent owner	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Cameron Turtle	officer: Chief Operating Officer	C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94104
Michael Thomas Henderson	director	421 KIPLING STREET, PALO ALTO CA 94301
Fairmount Healthcare Fund L.p.	director, 10 percent owner	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Fairmount Healthcare Fund Ii L.p.	director, 10 percent owner	200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN PA 19428
Tomas Kiselak	director, 10 percent owner	2001 MARKET STREET, SUITE 2500, PHILADELPHIA PA 19103
Jeff Marc Goldberg	director, officer: President and CEO	C/O AKCEA THERAPEUTICS, 55 CAMBRIDGE PARKWAY, STE 100, CAMBRIDGE MA 02142
Linda L Neuman	officer: Chief Medical Officer	C/O AEGLEA BIOTHERAPEUTICS, INC., 805 LAS CIMAS PARKWAY, SUITE 100, AUSTIN TX 78746
Marcio Souza	director	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
James Paul Kastenmayer	officer: Interim CEO & General Counsel	ONE MEDIMMUNE WAY, FLOOR ONE, AREA TWO, GAITHERSBURG MD 20879
Hanley Jr. Michael Conick	officer: Chief Commercial Officer	C/O AEGLEA THERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, #250, AUSTIN TX 78746